SciNeuro Pharmaceuticals Launches to Bring Innovative Treatments for CNS Diseases

0
84

SHANGHAI–(BUSINESS WIRE)–SciNeuro Pharmaceuticals (www.scineuro.com), focused on developing innovative medicines for patients with central nervous system (CNS) diseases, today announced its launch and a $100 million Series A financing, co-led by Lilly Asia Ventures Fund and Arch Venture Partners. They were joined by Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital and Zoo Capital. The funding is being used to build and advance a CNS product portfolio with initial focus on the Greater China region.

“One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patients – to their families and society as well,” said Min Li, Ph.D., Founder and Chief Executive Officer of SciNeuro. “I am humbled by the shared commitment from our investors. With their support, we are committed to addressing this substantial need by establishing a strong and innovative CNS product portfolio, and providing new and improved treatment options to patients in China and around the world.”

SciNeuro is targeting key CNS diseases for which there is major unmet need, and for which scientific progress may be translated into new and effective treatments. Through both internal R&D and strategic partnerships, SciNeuro is establishing a robust and differentiated pipeline to become a leading company focusing on CNS diseases.